Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
Witzig
Thomas E
TE
Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. witzig@mayo.edu
Silberstein
Peter T
PT
Loprinzi
Charles L
CL
Sloan
Jeff A
JA
Novotny
Paul J
PJ
Mailliard
James A
JA
Rowland
Kendrith M
KM
Alberts
Steven R
SR
Krook
James E
JE
Levitt
Ralph
R
Morton
Roscoe F
RF
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000139:chemically induced* / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001803:Blood Transfusion; D001943:Breast Neoplasms / Q000188:drug therapy; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007279:Injections, Subcutaneous; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D010919:Placebos; D011788:Quality of Life; D011994:Recombinant Proteins; D016896:Treatment Outcome
D006454:Hemoglobins; D010919:Placebos; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa